96 related articles for article (PubMed ID: 1361350)
1. Vaccine therapy using rgp 160 in early HIV infection.
Redfield R; Birx D; Ketter N; Polonis V; Johnson S; Davis C; Smith G; Oster C; Burke D
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1333. PubMed ID: 1361350
[No Abstract] [Full Text] [Related]
2. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
[No Abstract] [Full Text] [Related]
3. Properties of an HIV 'vaccine'.
Wahren B; Sandström E; Wigzell H
Nature; 1993 Apr; 362(6420):505; author reply 505-6. PubMed ID: 8464491
[No Abstract] [Full Text] [Related]
4. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
Bruck C; Thiriart C; Fabry L; Francotte M; Pala P; Van Opstal O; Culp J; Rosenberg M; De Wilde M; Heidt P; Heeney J
Vaccine; 1994 Sep; 12(12):1141-8. PubMed ID: 7998425
[TBL] [Abstract][Full Text] [Related]
5. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
[TBL] [Abstract][Full Text] [Related]
6. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. Clin Exp Immun 1994;98:178-84.
DePalma L
Pediatr AIDS HIV Infect; 1995 Apr; 6(2):97-8. PubMed ID: 11361387
[No Abstract] [Full Text] [Related]
8. Immunization of HIV-infected patients with rgp160: modulation of anti-rgp120 antibody spectrotype.
Biselli R; Loomis LD; Del Bono V; Burke DS; Redfield RR; Birx DL
J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1016-24. PubMed ID: 8083819
[TBL] [Abstract][Full Text] [Related]
9. Current approaches to vaccination against human immunodeficiency viruses.
Gluckman JC; Yagello M; Bahraoui E; Girard M
Allergol Immunopathol (Madr); 1991; 19(1):11-3. PubMed ID: 1719790
[No Abstract] [Full Text] [Related]
10. Human trials of AIDS vaccines: current status and future directions.
Koff WC; Fauci AS
AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
[No Abstract] [Full Text] [Related]
11. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
Kundu SK; Katzenstein D; Moses LE; Merigan TC
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
[TBL] [Abstract][Full Text] [Related]
12. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
Graham BS
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
[No Abstract] [Full Text] [Related]
13. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice.
Shirai A; Klinman DM
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):979-83. PubMed ID: 8280480
[TBL] [Abstract][Full Text] [Related]
14. Antibody and cellular responses after HIV immunization.
Wahren B
J Acquir Immune Defic Syndr (1988); 1994 Sep; 7(9):989. PubMed ID: 8051623
[No Abstract] [Full Text] [Related]
15. Retroviral vectors for HIV immunotherapy.
Warner JF; Jolly D; Mento S; Galpin J; Haubrich R; Merritt J
Ann N Y Acad Sci; 1995 Nov; 772():105-16. PubMed ID: 8546383
[No Abstract] [Full Text] [Related]
16. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
[No Abstract] [Full Text] [Related]
17. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.
Clerici M; Tacket CO; Via CS; Lucey DR; Muluk SC; Zajac RA; Boswell RN; Berzofsky JA; Shearer GM
Eur J Immunol; 1991 Jun; 21(6):1345-9. PubMed ID: 1845391
[TBL] [Abstract][Full Text] [Related]
18. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
[TBL] [Abstract][Full Text] [Related]
19. DNA inoculation induces cross clade anti-HIV-1 responses.
Wang B; Boyer J; Srikantan V; Ugen K; Agadjanian M; Merva M; Gilbert L; Dang K; McCallus D; Moelling K
Ann N Y Acad Sci; 1995 Nov; 772():186-97. PubMed ID: 8546392
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with gp160 in HIV.
Oyaizu N; Chirmule N; Pahwa S
N Engl J Med; 1992 Jan; 326(5):347; author reply 348. PubMed ID: 1728747
[No Abstract] [Full Text] [Related]
[Next] [New Search]
